Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Tata Medical Center

ClinicalTrials.gov lists Tata Medical Center as lead sponsor of 10 trials. It has 5 active development programs.

IN Hospital
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

3 0 2013 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.

Logo Kulbhushan Jhadav, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.

This page covers Tata Medical Center: 10 lead-sponsored trials and 1 legal-entity registration.

Get the Tata Medical Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (10)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Breast Neoplasms 3
Head and Neck Neoplasms 2
Frailty 1
Hypopharyngeal Neoplasms 1
Laryngeal Diseases 1

Trials by start year as sponsor or collaborator (8)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2025 1
2024 1
2021 2
2019 1
2018 3
2016 2
2015 1
2013 1

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (5)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Standard dose Head and Neck Neoplasms Not reported 1
Standard dose Hypopharyngeal Neoplasms Not reported 1
Standard dose Laryngeal Diseases Not reported 1
Standard dose Laryngeal Neoplasms Not reported 1
Standard dose Oropharyngeal Neoplasms Not reported 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
4 of 4 hit target (n=4) 50% on time (n=6)

Journals published in (27)

Shown in this order: most published in first.

Journals published in
Journal Publications
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 6
International journal of radiation oncology, biology, physics 5
The New England journal of medicine 5
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 4
Clinical oncology (Royal College of Radiologists (Great Britain)) 3

Latest dated events (12)

Shown in this order: newest first.

Latest dated events
Date Event Source
2025-04-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-08-07 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2021-11-23 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2021-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2019-03-26 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (12)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
IDS Trial sponsor Named in trial inclusion criteria
KITLG Trial sponsor Named in trial inclusion criteria
PTGDS Trial sponsor Named in trial inclusion criteria
SLC26A4 Trial sponsor Named in trial inclusion criteria
STT3A Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (50)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
EGFR 5
ERBB2 4
BTG1 3
NR3C1 3
TP53 3

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.